^
Association details:
| Biomarker: | EGFR N771delinsKG |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
Published date:
09/30/2020
Excerpt:
A 71-year-old non-smoker Chinese female was diagnosed with lung adenocarcinoma...The sequencing results in Figure 2 suggested that the patient had a novel EGFR ex20ins (N771delinsKG) mutation. Based on the NGS results, the patient started to receive first-line treatment with afatinib (40 mg/day) in July 2019....After one month of afatinib treatment, the size of the lesion in the left lower lung reduced markedly and that of the tumor lesion in the right lung was stable (Figure 3B). After four months of treatment (November 2019), the size of these lesions further decreased.
DOI:
https://doi.org/10.2147/OTT.S268694
